Citation

91 FR 2537

Multiple canonical documents share this first-page citation.

Minimal Residual Disease and Complete Response in Multiple Myeloma: Use as Endpoints To Support Accelerated Approval; Draft Guidance for Industry; Availability Wednesday, January 21, 2026 91 FR 2537
Notice of Approval of Product Under Voucher: Rare Pediatric Disease Priority Review Voucher; RHAPSIDO (Remibrutinib) Wednesday, January 21, 2026 91 FR 2537